Clinical Trial Update: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus for malignant pleural mesothelioma with Merlin/NF2 loss as a biomarker; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2015-04-20